IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Marcel Patek, et al

Examiner:

Not Yet Assigned

Art Unit:

1614

Application No.: 10/770,382

Filed: February 2, 2004

Title: Novel Cyclic Urea Derivatives, Preparation

Thereof And Pharmaceutical Use Thereof As

Kinase Inhibitors

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Mail Stop Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

 \boxtimes This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

(b)	This	mation Disclosure Statement is filed after the period set forth in 37 C.F.R.				
	1.97(b), but is believed to be filed before the mailing date of a final action under §1.113					
	or a	notice of allowance under §1.311, whichever occurs first.				
	(1)	The undersigned attorney certifies that each item of information contained in this				
		Information Disclosure Statement was cited in a communication from a foreign				
		patent office in a counterpart foreign application not more than three months prior				
		to the filing of this statement;				
	(2)	The undersigned attorney certifies that no item of information contained in this				
		Information Disclosure Statement was cited in a communication from a foreign				
		patent office in a counterpart foreign application or, to the knowledge of the				
		undersigned attorney after making reasonable inquiry, was known to any				
		individual designated in §1.56(c) more than three months prior to the filing of this				
		statement; or				
	(3)	This Information Disclosure Statement is accompanied by a transmittal letter in				
		which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is				
		authorized.				

Based on the new USPTO procedures, it is not required to submit copies of U.S. patents and U.S. publications for all applications filed after June 30, 2003. Therefore, a copy of the two (2) Patents Documents listed on the attached PTO-1449 form is not enclosed with this Information Disclosure Statement.

Respectfully submitted,

Joseph Strupczewski, Reg. No. 50,903

Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-2387
Telefax (908) 231-2626

Aventis Docket No. FRAV2003/0002 US NP

3	
n04 💥	
Pleasety	e a plus sign (+) inside this box ->

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

<i>``</i> ``````````````````````````````````	_	sign (+) inside this box	•		PTO/SB/08A (10-96) Approved for use through 10/31/99. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE spend to a collection of information unless it contains a valid OMB control number.		
TRADEMEN	Substitu	ute for form 1449A/PT(o		Complete if Known		
					Application Number	10/770,382	
	INF	ORMATION	DI	SCLOSURE	Filing Date	02-02-2004	
	STA	ATEMENT B	Y A	APPLICANT	First Named Inventor	MARCEL PATEK, et al	
				_	Group Art Unit	1614	
		(use as many she	ets a	s necessary)	Examiner Name		
	Sheet	1	of	1	Attorney Docket Number	FRAV2003/0002 - US - NP	

U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No. ¹	U.S. Patent Document Number Kind Code² (if known)		Name of Patentee or Applicant	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		4,097,578		PERRONNET, ET AL	06-27-1978		
		6,022,875		ZIMMER, ET AL	02-08-2000		
						······································	
					- -		
		<u> </u>			-		

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No. ¹	Office	Foreign Patent Do Number4	Cument Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6	
		EP	0584694		ZOLLER, ET AL	03-02-1994			
		EP	0770613		ZIMMER, ET AL	05-02-1997			
		wo	01/92253		SIRCAR, ET AL	12-06-2001			
		wo	98/39303		KELLY, ET AL	09-11-1998			
i									

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.